Skp2 Gene Copy Number Aberrations Are Common in Non-Small Cell Lung Carcinoma, and Its Overexpression in Tumors with ras Mutation Is a Poor Prognostic Marker

Clinical Cancer Research

Volumn 10, Issue 6, 2004, Pages 1984-1991

  Zhu, Chang Qi ^a   Blackhall, Fiona H ^b,c   Pintilie, Melania ^b   Iyengar, Pratibha ^c   Liu, Ni ^a   Ho, James ^a   Chomiak, Taylor ^a   Lau, Davina ^a   Winton, Timothy ^b,c,d   Shepherd, Frances A ^b,c   Tsao, Ming Sound ^a,b,c,e  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

^e PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA; PROTEIN P27;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CHROMOSOME 5P; FEMALE; GENE; GENE LOSS; GENE MUTATION; GENE NUMBER; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; ONCOGENE RAS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN CONTENT; PROTEIN EXPRESSION; SKP2 GENE;

ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CHROMOSOME ABERRATIONS; DNA PRIMERS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; S-PHASE KINASE-ASSOCIATED PROTEINS; SURVIVAL ANALYSIS;

EID: 12144288298     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0470     Document Type: Article

References (42)

1. Kip1. Biochem Biophys Res Commun 2001;282:853-60.
2. Kip1, polyploidy and centrosome overduplication. EMBO J 2000;19: 2069-81.
3. von der Lehr N, Johansson S, Wu S, Bahram F, Castell A, Cetinkaya C, Hydbring P, et al. The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription. Mol Cell 2003;11:1189-200.
4. Kim SY, Herbst A, Tworkowski KA, Salghetti SE, Tansey WP. Skp2 regulates Myc protein stability and activity. Mol Cell 2003;11:1177-88.
5. Bornstein G, Bloom J, Sitry-Shevah D, Nakayama K, Pagano M, Hershko A. Role of the SCFSkp2 ubiquitin ligase in the degradation of p21Cip1 in S phase. J Biol Chem 2003;278:25752-7.
6. Kamura T, Hara T, Kotoshiba S, Yada M, Ishida N, Imaki H, et al. Degradation of p57Kip2 mediated by SCFSkp2-dependent ubiquitylation. Proc Natl Acad Sci USA 2003;100:10231-6.
7. Bhattacharya S, Garriga J, Calbo J, Yong T, Haines DS, Grana X. SKP2 associates with p130 and accelerates p130 ubiquitylation and degradation in human cells. Oncogene 2003;22:2443-51.
8. Tedesco D, Lukas J, Reed SI. The pRb-related protein p130 is regulated by phosphorylation-dependent proteolysis via the protein-ubiquitin ligase SCF(Skp2). Genes Dev 2002;16:2946-57.
9. Oliveira AM, Okuno SH, Nascimento AG, Lloyd RV. Skp2 protein expression in soft tissue sarcomas. J Clin Oncol 2003;21:722-7.
10. Masuda TA, Inoue H, Sonoda H, Mine S, Yoshikawa Y, Nakayama K, et al. Clinical and biological significance of S-phase kinase-associated protein 2 (Skp2) gene expression in gastric carcinoma: modulation of malignant phenotype by Skp2 overexpression, possibly via p27 proteolysis. Cancer Res 2002;62:3819-25.
11. Yokoi S, Yasui K, Saito-Ohara F, Koshikawa K, Iizasa T, Fujisawa T, et al. A novel target gene, SKP2, within the 5p13 amplicon that is frequently detected in small cell lung cancers. Am J Pathol 2002;161: 207-16.
12. Zhang H, Kobayashi R, Galaktionov K, Beach D. p19Skp1 and p45Skp2 are essential elements of the cyclin A-CDK2 S phase kinase. Cell 1995;82:915-25.
13. Kip1 and proliferation index. Blood 2002;100:2950-6.
14. Yang G, Ayala G, Marzo AD, Tian W, Frolov A, Wheeler TM, et al. Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res 2002;8: 3419-26.
15. KIP1 down-regulation. Mod Pathol 2002;15: 1227-35.
16. Kudo Y, Kitajima S, Sato S, Miyauchi M, Ogawa I, Takata T. High expression of S-phase kinase-interacting protein 2, human F-box protein, correlates with poor prognosis in oral squamous cell carcinomas. Cancer Res 2001;61:7044-7.
17. Kip1 and of its ubiquitin ligase subunit Skp2 in colorectal carcinomas. Cancer 2001; 91:1745-51.
18. Gstaiger M, Jordan R, Lim M, Catzavelos C, Mestan J, Slingerland J, et al. Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci U S A 2001;98:5043-8.
19. Latres E, Chiarle R, Schulman BA, Pavletich NP, Pellicer A, Inghirami G, et al. Role of the F-box protein Skp2 in lymphomagenesis. Proc Natl Acad Sci U S A 2001;98:2515-20.
20. Inui N, Kitagawa K, Miwa S, Hattori T, Chida K, Nakamura H, et al. High expression of Cks1 in human non-small cell lung carcinomas. Biochem Biophys Res Commun 2003;303:978-84.
21. Kip1 in non-small cell lung carcinoma: a prognostic factor independent of Ras. Cancer Res 1999;59:684-8.
22. Kip1 protein levels independently predict outcome after breast cancer. J Clin Oncol 2000; 18:4045-52.
23. Sandhu C, Slingerland J. Deregulation of the cell cycle in cancer. Cancer Detect Prev 2000;24:107-18.
24. Tsihlias J, Kapusta L, Slingerland J. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Annu Rev Med 1999;50:401-23.
25. Luk C, Tsao MS, Bayani J, Shepherd F, Squire JA. Molecular cytogenetic analysis of non-small cell lung carcinoma by spectral karyotyping and comparative genomic hybridization. Cancer Genet Cytogenet 2001;125:87-99.
26. Petersen S, Aninat-Meyer M, Schluns K, Gellert K, Dietel M, Petersen I. Chromosomal alterations in the clonal evolution to the metastatic stage of squamous cell carcinomas of the lung. Br J Cancer 2000;82:65-73.
27. Levin NA, Brzoska PM, Warnock ML, Gray JW, Christman MF. Identification of novel regions of altered DNA copy number in small cell lung tumors. Genes Chromosomes Cancer 1995;13:175-85.
28. Michelland S, Gazzeri S, Brambilla E, Robert-Nicoud M. Comparison of chromosomal imbalances in neuroendocrine and non-small-cell lung carcinomas. Cancer Genet Cytogenet 1999;114:22-30.
29. Wang KK, Liu N, Radulovich N, Wigle DA, Johnston MR, Shepherd FA, et al. Novel candidate tumor marker genes for lung adenocarcinoma. Oncogene 2002;21:7598-604.
30. PE Applied Biosystems. User Bulletin #2: Relative quantitation of gene expression. Foster City, CA: Applied Biosystems; 1997.
31. Massion PP, Kuo WL, Stokoe D, Olshen AB, Treseler PA, Chin K, et al. Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway. Cancer Res 2002;62:3636-40.
32. Tsao MS, Liu N, Nicklee T, Shepherd F, Viallet J. Angiogenesis correlates with vascular endothelial growth factor expression but not with Ki-ras oncogene activation in non-small cell lung carcinoma. Clin Cancer Res 1997;3:1807-14.
33. Pei J, Balsara BR, Li W, Litwin S, Gabrielson E, Feder M, et al. Genomic imbalances in human lung adenocarcinomas and squamous cell carcinomas. Genes Chromosomes Cancer 2001;31:282-7.
34. Shigemasa K, Gu L, O'Brien TJ, Ohama K. Skp2 overexpression is a prognostic factor in patients with ovarian adenocarcinoma. Clin Cancer Res 2003;9:1756-63.
35. Chao Y, Shih YL, Chiu JH, Chau GY, Lui WY, Yang WK, et al. Overexpression of cyclin A but not Skp 2 correlates with the tumor relapse of human hepatocellular carcinoma. Cancer Res 1998;58: 985-90.
36. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 2002;122: 1037-57.
37. Huncharek M, Muscat J, Geschwind JF. K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases. Carcinogenesis (Lond.) 1999;20:1507-10.
38. Carrano AC, Eytan E, Hershko A, Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1999;1:193-9.
39. Dowen SE, Scott A, Mukherjee G, Stanley MA. Overexpression of Skp2 in carcinoma of the cervix does not correlate inversely with p27 expression. Int J Cancer 2003;105:326-30.
40. Kip1 by two mechanisms, ubiquitin-mediated degradation and proteolytic processing. J Biol Chem 1999;274:13886-93.
41. 1 transition mediated by a Skp2-independent ubiquitination pathway. J Biol Chem 2001;276: 48937-43.
42. Kip1 ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. Curr Biol 1999;9:661-4.